ADVERTISEMENT

Human Proteome Project (HPP): Blueprint Covering 90.4% of the Human Proteome Released

Human Proteome Project (HPP) was launched in 2010 after successful completion of Human Genome Project (HGP) to identify, characterise and map human proteome (the entire set of proteins expressed by the human genome). On its tenth anniversary, HPP has released the first high-stringency blueprint that covers 90.4% of the human proteome. As the code of life, this milestone has very significant implications for human health and therapeutics.   

Completed in 2003, Human Genome Project (HGP) was an international collaboration set up in 1990 with an aim to identify the complete set of human genes and to determine the complete sequence of DNA bases in the human genome. On January 15, 2001, HGP had released initial sequence and analysis of the human genome. Identifying, characterizing and mapping of human proteome (entire complement of proteins coded by the genome) was the next logical step. Therefore, Human Proteome Organization (HUPO) was formed on February 9, 2001 to promote proteomics research. On September 23, 2010 HUPO officially launched Human Proteome Project (HPP) with an aim to prepare a blueprint of the human proteome (1).  

The analysis of the human genome predicts around 20,300 protein-coding genes. The entire set of proteins coded by these genes constitute the ‘human proteome’. Human proteome is much larger than ‘human genome’ because one gene can be expressed in range of forms (proteoforms) as a result of chemical modifications during and after translation. It is estimated that a million proteoforms may coexist in a single individual. In 2010, at the start of HPP, barely 70% of the proteins predicted by the genome analysis were identified. The agenda of the proteome project was to fill this knowledge gap. With the advances in technology, it has become possible to detect and quantify proteins and their forms with higher precision. Still, there are a good number of missing proteins (proteins predicted by the genome analysis, but still undetected) (2,3). The project is still in progress; however, a milestone has been reached. 

On October 16, 2020 on its tenth anniversary, HPP released the first high-stringency blueprint that covers 90.4% of the human proteome (1). This considerably improves our knowledge of human biology and understanding of the molecular mechanisms at cellular and molecular level, especially the role played by human proteome which directly leads to performing research and development of diagnostics and therapeutics for cancers, cardiovascular and infectious diseases particularly for personalised and precision medicine (4)

The development of Human Protein Atlas presents a very significant progress for further research in the area of human diagnostics and therapeutics (5,6).  

***

References:

  1. HUPO 2021. Proteomics Timeline. Available on https://hupo.org/Proteomics-Timeline.  
  1. neXtProt 2021. The human proteome. Available online at https://www.nextprot.org/about/human-proteome Accessed on 30 December 2020. 
  1. Inserm, 2020. Proteomics: the code of life translated by more than 90%. Posted 07 December 2020. Available online at https://www.inserm.fr/actualites-et-evenements/actualites/proteomique-code-vie-traduit-plus-90 Accessed on 30 December 2020.  
  1. Adhikari, S., Nice, E.C., Deutsch, E.W. et al. 2020. A high-stringency blueprint of the human proteome. Published: 16 October 2020. Nature Communication 11, 5301 (2020). DOI: https://doi.org/10.1038/s41467-020-19045-9  
  1. Digre A., and Lindskog C., 2020. The Human Protein Atlas – Spatial localization of the human proteome in health and disease. Protein Science Volume 30, Issue 1. First published: 04 November 2020. DOI: https://doi.org/10.1002/pro.3987  
  1. The Human Protein Atlas 2020.  Human Protein Atlas Available online at https://www.proteinatlas.org/about Accessed on 30 December 2020. 

***

Umesh Prasad
Umesh Prasad
Science journalist | Founder editor, Scientific European magazine

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

Sotrovimab Approval in the UK: A Monoclonal Antibody Effective Against Omicron, may work for...

Sotrovimab, a monoclonal antibody already approved for mild to...

Omega-3 Supplements May Not Offer Benefit to The Heart

An elaborate comprehensive study shows Omega-3 supplements may not...

Lecanemab for Early Alzheimer’s Disease approved in the UK but refused in EU 

Monoclonal antibodies (mAbs) lecanemab and donanemab have been approved...
- Advertisement -
93,316FansLike
47,364FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe